Therapeuticsmd Inc (TXMD)

$2.06 +0.03 (1.48%)
Market Cap 23.50M
Revenue (ttm) 3.02M
Net Income (ttm) -570,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.87%
Debt to Equity Ratio 0.00
Volume 25,500
Avg Vol 33,216
Day's Range N/A - N/A
Shares Out 11.57M
Stochastic %K 34%
Beta 0.61
Analysts Strong Buy
Price Target $5.00

Company Profile

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 561 961 1900
Address:
951 Yamato Road, Suite 220, Boca Raton, United States
JopyBo
JopyBo Aug. 20 at 11:14 PM
$TXMD Time to reset your sell order. I had 7... haha. Still think we double at least if they win case overall. So ... new sell order for about 4.8. Half only. Then sit in it again For who knows how long
0 · Reply
vijalp9
vijalp9 Aug. 12 at 8:53 PM
$TXMD Q2 earnings uneventful, but cool tidbit of upcoming cash influx — In July 2026, Knight notified the Company that the net sales milestone related to IMVEXXY sales for the year ended December 31, 2025 had been achieved. Accordingly, the Company became entitled to receive a milestone payment of CAD 500.0 thousand, equivalent to $364.8 thousand, and recognized the related license revenue during the three months ended September 30, 2026.
0 · Reply
jfer333
jfer333 Jul. 23 at 11:34 PM
$TXMD docket update: BDO can’t conduct the expert determination because of auditor-independence rules, so Mayne filed an unopposed motion to replace BDO with RSM US LLP. TXMD agreed, and Judge Connolly granted it the same day. RSM will now make the final and binding determination on the disputed true-up items, the case remains stayed, and the parties must report back within one week after RSM finishes. Biggest takeaway: the procedural roadblocks are gone and the case is finally moving toward an actual number, which should make any settlement, restructuring, or asset transaction much easier to negotiate.
1 · Reply
hiTHit
hiTHit Jul. 9 at 5:39 PM
$TXMD Alright, the markets are open; you can start sharing your most idiotic ideas with us.
1 · Reply
Yeah_No_Yeah
Yeah_No_Yeah Jul. 8 at 2:56 PM
$TXMD
0 · Reply
hiTHit
hiTHit Jul. 6 at 5:50 PM
$TXMD I wish the price had gone back to 1$; because 1 is a higher-quality number than 2—it's first-class.
0 · Reply
Kobe2324
Kobe2324 Jul. 6 at 1:44 PM
$TXMD so happy I got out of this dog crap. Made some money but made already so much more leaving
0 · Reply
Rohfiq
Rohfiq Jul. 1 at 10:56 PM
$TXMD Come on
0 · Reply
MadStockAlerts1
MadStockAlerts1 Jun. 30 at 5:25 PM
$TXMD flashing a bullish MACD cross on the daily
1 · Reply
topstockalerts
topstockalerts Jun. 30 at 3:46 PM
$TXMD $3+ ahead
0 · Reply
Latest News on TXMD
TherapeuticsMD Announces Second Quarter 2026 Financial Results

Aug 11, 2026, 4:00 PM EDT - 9 days ago

TherapeuticsMD Announces Second Quarter 2026 Financial Results

TherapeuticsMD Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 9 days ago

TherapeuticsMD Earnings release: Q2 2026

TherapeuticsMD Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 9 days ago

TherapeuticsMD Quarterly report: Q2 2026

TherapeuticsMD reports Q1 EPS 1c vs. (6c) last year

2026-05-12T21:18:55.000Z - 3 months ago

TherapeuticsMD reports Q1 EPS 1c vs. (6c) last year

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026, 4:05 PM EDT - 3 months ago

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

TherapeuticsMD Earnings release: Q1 2026

TherapeuticsMD Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

TherapeuticsMD Quarterly report: Q1 2026

TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year

2026-03-30T20:23:59.000Z - 5 months ago

TherapeuticsMD reports FY25 EPS (6c) vs. (20c) last year

TherapeuticsMD Announces Full Year 2025 Financial Results

Mar 30, 2026, 4:05 PM EDT - 5 months ago

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

TherapeuticsMD Earnings release: Q4 2025

TherapeuticsMD Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

TherapeuticsMD Annual report: Q4 2025

TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year

2025-11-12T21:15:33.000Z - 10 months ago

TherapeuticsMD reports Q3 EPS 0c vs. (5c) last year

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Nov 12, 2025, 4:05 PM EST - 10 months ago

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Earnings release: Q3 2025

Nov 6, 2025, 6:00 AM EST - 10 months ago

TherapeuticsMD Earnings release: Q3 2025

TherapeuticsMD Quarterly report: Q3 2025

Nov 6, 2025, 6:00 AM EST - 10 months ago

TherapeuticsMD Quarterly report: Q3 2025

TherapeuticsMD Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 10 months ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 10 months ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 10 months ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

2025-08-12T20:40:35.000Z - 1 year ago

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

TherapeuticsMD Announces Second Quarter 2025 Financial Results

Aug 12, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces Second Quarter 2025 Financial Results

TherapeuticsMD Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Quarterly report: Q2 2025

TherapeuticsMD Earnings release: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Earnings release: Q2 2025

TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year

2025-05-13T20:15:52.000Z - 1 year ago

TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces First Quarter 2025 Financial Results

TherapeuticsMD Quarterly report: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Quarterly report: Q1 2025

TherapeuticsMD Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

TherapeuticsMD Earnings release: Q1 2025

TherapeuticsMD Announces Full Year 2024 Financial Results

Mar 27, 2025, 4:05 PM EDT - 1 year ago

TherapeuticsMD Announces Full Year 2024 Financial Results

TherapeuticsMD Annual report: Q4 2024

Mar 27, 2025, 2:00 AM EDT - 1 year ago

TherapeuticsMD Annual report: Q4 2024

TherapeuticsMD Earnings release: Q4 2024

Mar 27, 2025, 2:00 AM EDT - 1 year ago

TherapeuticsMD Earnings release: Q4 2024

TherapeuticsMD Announces Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

TherapeuticsMD Announces Third Quarter 2024 Financial Results

TherapeuticsMD Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

TherapeuticsMD Earnings release: Q3 2024

TherapeuticsMD Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

TherapeuticsMD Quarterly report: Q3 2024

TherapeuticsMD Proxy statement: Proxy Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Proxy statement: Proxy Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Quarterly report: Q2 2024

Aug 23, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Quarterly report: Q2 2024

TherapeuticsMD Earnings release: Q2 2024

Aug 23, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Earnings release: Q2 2024

TherapeuticsMD Announces Second Quarter 2024 Financial Results

Aug 12, 2024, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces Second Quarter 2024 Financial Results

TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year

2024-05-10T20:06:17.000Z - 2 years ago

TherapeuticsMD reports Q1 EPS (7c) vs (24c) last year

TherapeuticsMD Announces First Quarter 2024 Financial Results

May 10, 2024, 4:05 PM EDT - 2 years ago

TherapeuticsMD Announces First Quarter 2024 Financial Results

TherapeuticsMD Quarterly report: Q1 2024

May 10, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Quarterly report: Q1 2024

TherapeuticsMD Earnings release: Q1 2024

May 10, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Earnings release: Q1 2024

TherapeuticsMD Announces Full Year 2023 Financial Results

Mar 29, 2024, 4:00 PM EDT - 2 years ago

TherapeuticsMD Announces Full Year 2023 Financial Results

TherapeuticsMD Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

TherapeuticsMD Earnings release: Q4 2023

TherapeuticsMD Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

TherapeuticsMD Annual report: Q4 2023

TherapeuticsMD Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 3 years ago

TherapeuticsMD Announces Third Quarter 2023 Financial Results

TherapeuticsMD Quarterly report: Q3 2023

Nov 14, 2023, 4:00 PM EST - 3 years ago

TherapeuticsMD Quarterly report: Q3 2023

TherapeuticsMD Earnings release: Q3 2023

Nov 14, 2023, 4:00 PM EST - 3 years ago

TherapeuticsMD Earnings release: Q3 2023

TherapeuticsMD Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Quarterly report: Q2 2023

TherapeuticsMD Earnings release: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q2 2023

TherapeuticsMD reports Q2 EPS (24c) vs. ($1.70) last year

2023-08-14T10:51:58.000Z - 3 years ago

TherapeuticsMD reports Q2 EPS (24c) vs. ($1.70) last year

TherapeuticsMD Announces Second Quarter 2023 Financial Results

Aug 14, 2023, 6:50 AM EDT - 3 years ago

TherapeuticsMD Announces Second Quarter 2023 Financial Results

TherapeuticsMD Proxy statement: Proxy Filing

May 17, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Proxy statement: Proxy Filing

May 17, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Announces First Quarter 2023 Financial Results

May 15, 2023, 4:05 PM EDT - 3 years ago

TherapeuticsMD Announces First Quarter 2023 Financial Results

TherapeuticsMD Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Quarterly report: Q1 2023

TherapeuticsMD Earnings release: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q1 2023

TherapeuticsMD Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

TherapeuticsMD Proxy statement: Proxy Filing

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Apr 7, 2023, 4:01 PM EDT - 3 years ago

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

TherapeuticsMD Annual report: Q4 2022

Apr 7, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Annual report: Q4 2022

TherapeuticsMD Earnings release: Q4 2022

Apr 7, 2023, 7:00 AM EDT - 3 years ago

TherapeuticsMD Earnings release: Q4 2022

TherapeuticsMD reinstated with a Neutral at Cantor Fitzgerald

2023-01-11T12:20:19.000Z - 3 years ago

TherapeuticsMD reinstated with a Neutral at Cantor Fitzgerald

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Jan 3, 2023, 6:50 AM EST - 3 years ago

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

TherapeuticsMD Inks Licensing Deal with Mayne Pharma

2022-12-05T07:39:07.000Z - 4 years ago

TherapeuticsMD Inks Licensing Deal with Mayne Pharma

TherapeuticsMD enters agreements to license products to Mayne Pharma

2022-12-04T23:04:12.000Z - 4 years ago

TherapeuticsMD enters agreements to license products to Mayne Pharma

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Dec 4, 2022, 6:00 PM EST - 4 years ago

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

TherapeuticsMD reports Q3 EPS ($3.13) vs. ($5.62) a year ago

2022-11-14T21:10:01.000Z - 4 years ago

TherapeuticsMD reports Q3 EPS ($3.13) vs. ($5.62) a year ago

TherapeuticsMD Announces Third Quarter 2022 Financial Results

Nov 14, 2022, 4:05 PM EST - 4 years ago

TherapeuticsMD Announces Third Quarter 2022 Financial Results

TherapeuticsMD Quarterly report: Q3 2022

Nov 14, 2022, 9:00 AM EST - 4 years ago

TherapeuticsMD Quarterly report: Q3 2022

TherapeuticsMD Slides: Q3 2022

Nov 14, 2022, 9:00 AM EST - 4 years ago

TherapeuticsMD Slides: Q3 2022

TherapeuticsMD Announces Additional $7 Million Private Placement

Oct 31, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Additional $7 Million Private Placement

TherapeuticsMD Announces $7 Million Private Placement

Oct 3, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces $7 Million Private Placement

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Sep 12, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

TherapeuticsMD Earnings Call Transcript: Q2 2022

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q2 2022

TherapeuticsMD Quarterly report: Q2 2022

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Quarterly report: Q2 2022

TherapeuticsMD Slides: Q2 2022

Aug 15, 2022, 7:15 AM EDT - 4 years ago

TherapeuticsMD Slides: Q2 2022

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Aug 15, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Second Quarter 2022 Financial Results

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

Aug 8, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

Leading Insider Makes Private Investment in TherapeuticsMD Worth $15M

2022-08-02T14:56:40.000Z - 4 years ago

Leading Insider Makes Private Investment in TherapeuticsMD Worth $15M

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Aug 1, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

TherapeuticsMD's stock falls 41% after tender offer expires

Jul 13, 2022, 8:25 AM EDT - 4 years ago

TherapeuticsMD's stock falls 41% after tender offer expires

TherapeuticsMD Announces Expiration of Tender Offer

Jul 13, 2022, 6:50 AM EDT - 4 years ago

TherapeuticsMD Announces Expiration of Tender Offer

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

Jul 6, 2022, 6:09 AM EDT - 4 years ago

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

Jun 6, 2022, 4:05 PM EDT - 4 years ago

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

May 31, 2022, 7:34 PM EDT - 4 years ago

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

Here is why TherapeuticsMD jumped 300%

May 31, 2022, 1:57 PM EDT - 4 years ago

Here is why TherapeuticsMD jumped 300%

EW Healthcare Partners Acquires TherapeuticsMD; TXMD Shares Surge 350%

2022-05-31T13:53:53.000Z - 4 years ago

EW Healthcare Partners Acquires TherapeuticsMD; TXMD Shares Surge 350%

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

May 31, 2022, 6:00 AM EDT - 4 years ago

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

May 20, 2022, 9:43 AM EDT - 4 years ago

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

TherapeuticsMD Announces First Quarter 2022 Financial Results

May 16, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD Announces First Quarter 2022 Financial Results

TherapeuticsMD Earnings Call Transcript: Q1 2022

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q1 2022

TherapeuticsMD Quarterly report: Q1 2022

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Quarterly report: Q1 2022

TherapeuticsMD Slides: Q1 2022

May 16, 2022, 9:13 AM EDT - 4 years ago

TherapeuticsMD Slides: Q1 2022

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

May 10, 2022, 4:05 PM EDT - 4 years ago

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Apr 14, 2022, 4:15 PM EDT - 4 years ago

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

GDRX

TherapeuticsMD Earnings Call Transcript: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings Call Transcript: Q4 2021

TherapeuticsMD Earnings release: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Earnings release: Q4 2021

TherapeuticsMD Annual report: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Annual report: Q4 2021

TherapeuticsMD Slides: Q4 2021

Mar 10, 2022, 8:30 AM EST - 4 years ago

TherapeuticsMD Slides: Q4 2021

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Mar 10, 2022, 6:50 AM EST - 4 years ago

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

Mar 7, 2022, 7:40 AM EST - 4 years ago

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

GDRX

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

Mar 1, 2022, 4:30 PM EST - 4 years ago

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

Dec 10, 2021, 4:30 PM EST - 5 years ago

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

Dec 8, 2021, 6:50 AM EST - 5 years ago

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

TherapeuticsMD Earnings Call Transcript: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Earnings Call Transcript: Q3 2021

TherapeuticsMD Quarterly report: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Quarterly report: Q3 2021

TherapeuticsMD Earnings release: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Earnings release: Q3 2021

TherapeuticsMD Slides: Q3 2021

Nov 11, 2021, 8:30 AM EST - 5 years ago

TherapeuticsMD Slides: Q3 2021

TherapeuticsMD Announces Third Quarter 2021 Financial Results

Nov 11, 2021, 6:50 AM EST - 5 years ago

TherapeuticsMD Announces Third Quarter 2021 Financial Results

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

Nov 11, 2021, 6:45 AM EST - 5 years ago

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

Oct 27, 2021, 5:00 PM EDT - 5 years ago

TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Oct 15, 2021, 5:33 PM EDT - 5 years ago

TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Sep 21, 2021, 7:45 AM EDT - 5 years ago

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness Month

Sep 2, 2021, 6:50 AM EDT - 5 years ago

Therapeutics MD Is Urging Women to ‘Take Pause' During Menopause Awareness Month

JopyBo
JopyBo Aug. 20 at 11:14 PM
$TXMD Time to reset your sell order. I had 7... haha. Still think we double at least if they win case overall. So ... new sell order for about 4.8. Half only. Then sit in it again For who knows how long
0 · Reply
vijalp9
vijalp9 Aug. 12 at 8:53 PM
$TXMD Q2 earnings uneventful, but cool tidbit of upcoming cash influx — In July 2026, Knight notified the Company that the net sales milestone related to IMVEXXY sales for the year ended December 31, 2025 had been achieved. Accordingly, the Company became entitled to receive a milestone payment of CAD 500.0 thousand, equivalent to $364.8 thousand, and recognized the related license revenue during the three months ended September 30, 2026.
0 · Reply
jfer333
jfer333 Jul. 23 at 11:34 PM
$TXMD docket update: BDO can’t conduct the expert determination because of auditor-independence rules, so Mayne filed an unopposed motion to replace BDO with RSM US LLP. TXMD agreed, and Judge Connolly granted it the same day. RSM will now make the final and binding determination on the disputed true-up items, the case remains stayed, and the parties must report back within one week after RSM finishes. Biggest takeaway: the procedural roadblocks are gone and the case is finally moving toward an actual number, which should make any settlement, restructuring, or asset transaction much easier to negotiate.
1 · Reply
hiTHit
hiTHit Jul. 9 at 5:39 PM
$TXMD Alright, the markets are open; you can start sharing your most idiotic ideas with us.
1 · Reply
Yeah_No_Yeah
Yeah_No_Yeah Jul. 8 at 2:56 PM
$TXMD
0 · Reply
hiTHit
hiTHit Jul. 6 at 5:50 PM
$TXMD I wish the price had gone back to 1$; because 1 is a higher-quality number than 2—it's first-class.
0 · Reply
Kobe2324
Kobe2324 Jul. 6 at 1:44 PM
$TXMD so happy I got out of this dog crap. Made some money but made already so much more leaving
0 · Reply
Rohfiq
Rohfiq Jul. 1 at 10:56 PM
$TXMD Come on
0 · Reply
MadStockAlerts1
MadStockAlerts1 Jun. 30 at 5:25 PM
$TXMD flashing a bullish MACD cross on the daily
1 · Reply
topstockalerts
topstockalerts Jun. 30 at 3:46 PM
$TXMD $3+ ahead
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 2:32 PM
$TXMD fresh alert wants to run
0 · Reply
topstockalerts
topstockalerts Jun. 30 at 12:31 PM
$TXMD due for a nice pop soon 🚨📈
0 · Reply
Zskylar
Zskylar Jun. 29 at 9:13 PM
$TXMD never took off. No volume
0 · Reply
Zskylar
Zskylar Jun. 29 at 7:09 PM
$TXMD need some volume
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 7:03 PM
$TXMD can’t say you weren’t warned 🚨🚨🚨
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 5:33 PM
$TXMD fresh alert breaking out 📈
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 4:38 PM
$TXMD setting up for a nice rally
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 3:46 PM
$TXMD let’s go team 💵💵💵👏
0 · Reply
MadStockAlerts1
MadStockAlerts1 Jun. 29 at 3:28 PM
$TXMD waking back up.
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 3:16 PM
$TXMD fresh alert wants to go parabolic 🔥🔥🔥
0 · Reply
MadStockAlerts1
MadStockAlerts1 Jun. 29 at 3:15 PM
$TXMD just flashed a bullish MACD cross on the daily. Worth keeping on your radar.
0 · Reply
topstockalerts
topstockalerts Jun. 29 at 2:14 PM
$TXMD upside resumes
0 · Reply